TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

BACKGROUND: The negative prognostic and predictive value of TP53 co-mutations (TP53 mt+) in EGFR mutated (EGFR mt+) non-small cell lung cancer (NSCLC) is increasingly being acknowledged. Data consistently show that TP53 mt+ impact negatively on 1st line objective response rate (ORR), progression fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Roeper, Julia, Christopoulos, Petros, Falk, Markus, Heukamp, Lukas C., Tiemann, Markus, Stenzinger, Albrecht, Thomas, Michael, Griesinger, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825660/
https://www.ncbi.nlm.nih.gov/pubmed/35242623
http://dx.doi.org/10.21037/tlcr-21-754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825660/
https://www.ncbi.nlm.nih.gov/pubmed/35242623
http://dx.doi.org/10.21037/tlcr-21-754

Ejemplares similares